Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.

Roudnicky F, Yoon SY, Poghosyan S, Schwager S, Poyet C, Vella G, Bachmann SB, Karaman S, Shin JW, Otto VI, Detmar M.

Oncogene. 2018 May;37(19):2573-2585. doi: 10.1038/s41388-018-0129-z. Epub 2018 Feb 22.

2.

Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery.

Christensen K, Roudnicky F, Patsch C, Burcin M.

Adv Biochem Eng Biotechnol. 2018;163:207-220. doi: 10.1007/10_2017_23.

PMID:
29071405
3.

An integrated expression atlas of miRNAs and their promoters in human and mouse.

de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, Ashoor H, Åström G, Babina M, Bertin N, Burroughs AM, Carlisle AJ, Daub CO, Detmar M, Deviatiiarov R, Fort A, Gebhard C, Goldowitz D, Guhl S, Ha TJ, Harshbarger J, Hasegawa A, Hashimoto K, Herlyn M, Heutink P, Hitchens KJ, Hon CC, Huang E, Ishizu Y, Kai C, Kasukawa T, Klinken P, Lassmann T, Lecellier CH, Lee W, Lizio M, Makeev V, Mathelier A, Medvedeva YA, Mejhert N, Mungall CJ, Noma S, Ohshima M, Okada-Hatakeyama M, Persson H, Rizzu P, Roudnicky F, Sætrom P, Sato H, Severin J, Shin JW, Swoboda RK, Tarui H, Toyoda H, Vitting-Seerup K, Winteringham L, Yamaguchi Y, Yasuzawa K, Yoneda M, Yumoto N, Zabierowski S, Zhang PG, Wells CA, Summers KM, Kawaji H, Sandelin A, Rehli M; FANTOM Consortium, Hayashizaki Y, Carninci P, Forrest ARR, de Hoon MJL.

Nat Biotechnol. 2017 Sep;35(9):872-878. doi: 10.1038/nbt.3947. Epub 2017 Aug 21.

4.

High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.

Roudnicky F, Dieterich LC, Poyet C, Buser L, Wild P, Tang D, Camenzind P, Ho CH, Otto VI, Detmar M.

J Pathol. 2017 Jun;242(2):193-205. doi: 10.1002/path.4892. Epub 2017 May 3.

5.

Transcriptional profiling of macrophage and tumor cell interactions in vitro.

Roudnicky F, Hollmén M.

Genom Data. 2016 Feb 22;8:1-3. doi: 10.1016/j.gdata.2016.02.009. eCollection 2016 Jun.

6.

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C.

Dis Markers. 2015;2015:785461. doi: 10.1155/2015/785461. Epub 2015 Oct 12.

7.

Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ.

J Clin Pathol. 2015 Oct;68(10):819-24. doi: 10.1136/jclinpath-2015-202898. Epub 2015 Aug 6.

8.

Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.

Hollmén M, Roudnicky F, Karaman S, Detmar M.

Sci Rep. 2015 Mar 17;5:9188. doi: 10.1038/srep09188.

9.

Steering target selectivity and potency by fragment-based de novo drug design.

Rodrigues T, Kudoh T, Roudnicky F, Lim YF, Lin YC, Koch CP, Seno M, Detmar M, Schneider G.

Angew Chem Int Ed Engl. 2013 Sep 16;52(38):10006-9. doi: 10.1002/anie.201304847. Epub 2013 Aug 26.

PMID:
24030898
10.

Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis.

Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stöhr R, Hartmann A, Provenzano M, Otto VI, Detmar M.

Cancer Res. 2013 Feb 1;73(3):1097-106. doi: 10.1158/0008-5472.CAN-12-1855. Epub 2012 Dec 14.

11.

Inflammation-induced lymph node lymphangiogenesis is reversible.

Mumprecht V, Roudnicky F, Detmar M.

Am J Pathol. 2012 Mar;180(3):874-9. doi: 10.1016/j.ajpath.2011.11.010. Epub 2011 Dec 23.

Supplemental Content

Loading ...
Support Center